Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection

[1]  R. Ribeiro,et al.  Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants , 2022, The New England journal of medicine.

[2]  S. E. Reese,et al.  Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[3]  Gheyath K Nasrallah,et al.  Duration of immune protection of SARS-CoV-2 natural infection against reinfection , 2022, medRxiv.

[4]  Qian Wang,et al.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.

[5]  D. Parums.  Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2 , 2022, Medical science monitor : international medical journal of experimental and clinical research.

[6]  O. Pybus,et al.  Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.

[7]  D. Barouch,et al.  Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 , 2022, The New England journal of medicine.

[8]  G. Lozanski,et al.  Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, The New England journal of medicine.

[9]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[10]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[11]  P. Klenerman,et al.  Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum , 2022, Cell.

[12]  B. Clotet,et al.  Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities , 2022, Age and ageing.

[13]  M. Nussenzweig,et al.  Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost , 2022, Nature.

[14]  P. Maes,et al.  Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies , 2022, Nature Medicine.

[15]  A. Sette,et al.  Humoral and cellular immune memory to four COVID-19 vaccines , 2022, Cell.

[16]  Gheyath K Nasrallah,et al.  Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.

[17]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[18]  A. Charlett,et al.  Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection , 2022, The New England journal of medicine.

[19]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[20]  S. Vermund,et al.  Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.

[21]  Christopher J. L. Murray,et al.  COVID-19 will continue but the end of the pandemic is near , 2022, The Lancet.

[22]  C. Riou,et al.  Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose , 2022, The Lancet.

[23]  S. Madhi,et al.  SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.

[24]  P. Schommers,et al.  mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant , 2021, Nature Medicine.

[25]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[26]  H. Ullum,et al.  Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study , 2022, SSRN Electronic Journal.

[27]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[28]  M. Nussenzweig,et al.  Plasma Neutralization of the SARS-CoV-2 Omicron Variant , 2021, The New England journal of medicine.

[29]  T. Ndung’u,et al.  Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.

[30]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[31]  A. Telenti,et al.  Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.

[32]  M. Kraemer,et al.  Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.

[33]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[34]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[35]  F. Rieux-Laucat,et al.  Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection , 2021, Nature Immunology.

[36]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[37]  Frances E. Muldoon,et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[38]  A. Fontanet,et al.  Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2 , 2021, The Journal of infectious diseases.

[39]  H. Mouquet,et al.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.

[40]  C. Rice,et al.  Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.

[41]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[42]  Y. Yazdanpanah,et al.  A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations , 2020, Science Translational Medicine.

[43]  H. Mouquet,et al.  Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.

[44]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[45]  K. Black,et al.  bioRxiv: the preprint server for biology , 2019, bioRxiv.